Design, synthesis and anti-mycobacterial evaluation of imidazo[1,2-<i>a</i>]pyridine analogues-Reference-Cited by-同舟云学术

Design, synthesis and anti-mycobacterial evaluation of imidazo[1,2-a]pyridine analogues

Published:2022 Issue:3 Volume:13 Page:327-342
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Khetmalis Yogesh Mahadu¹,Chitti Surendar¹,Umarani Wunnava Anjani²,Karan Kumar Banoth³^ORCID,Murali Krishna Kumar Muthyala²,Murugesan Sankaranarayanan³^ORCID,Chandra Sekhar Kondapalli Venkata Gowri¹^ORCID

Affiliation:

1. Department of Chemistry, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad 500 078, Telangana, India

2. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, 530 003, India

3. Medicinal Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani, 333031, India

Abstract

34 imidazo[1,2-a]pyridine amides & sulfonamides are synthesized & evaluated for in vitro anti-TB activity against MTB H37Rv. IPA-6 is most potent with MIC 0.05 μg mL−1 & 125 times active than ethambutol & docked to MTB enoyl acyl protein reductase.

Funder

Council of Scientific and Industrial Research, India

Birla Institute of Technology and Science, Pilani

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/MD/D1MD00367D

Reference33 articles.

1. Respiratory ATP synthesis: the new generation of mycobacterial drug targets?

2. Latent tuberculosis infection: An overview